跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
INFUTRAZE CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
INFUTRAZE CONCENTRADO PARA SOLUCION PARA PERFUSION
Approved
STANDARD
INFUTRAZE CONCENTRADO PARA SOLUCION PARA PERFUSION
Fresenius Kabi España, S.A.U.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 27, 2023
Approval ID
4a78480bbb384475
Company
Fresenius Kabi España, S.A.U.
Type
Standard
Approval Details
Approval Id
4a78480bbb384475
Drug Cima Aemps Name
INFUTRAZE CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number
88927
Holder Company Name
Fresenius Kabi España, S.A.U.
Marketing Company Name
Fresenius Kabi España, S.A.U.
Authorization Date
2023-06-27
Dosage Form
CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose
-
Route Of Administration
VÍA INTRAVENOSA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Fresenius Kabi España, S.A.U.
Active Ingredients
COBRE CLORURO DIHIDRATO
107,40 µg
MANGANESO (CLORURO DE) TETRAHIDRATO
3,60 µg
POTASIO IODURO
2,56 µg
SELENITO SODIO ANHIDRO
15,33 µg
ZINC CLORURO
1042 µg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 27, 2023
Approval ID
4a78480bbb384475
Type
Standard
Back to CIMA-AEMPS Approvals
